

- 1 -

SEQUENCE LISTING

<110> CSL LIMITED

<120> Immunogenic Complexes and Methods Relating Thereto

<130> TDO

<140> International

<141> 2000-02-17

<150> PP8735/99

<151> 1999-02-17

<150> PQ1861/99

<151> 1999-02-17

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 11

<212> PRT

<213> mammalian

<400> 1

Ser Leu Leu Met Trp Ile Thr Gln Cys Phe Leu

1

5

10

<210> 2

<211> 9

<212> PRT

<213> mammalian

<400> 2

Ser Leu Leu Met Trp Ile Thr Gln Cys

1

5

- 2 -

&lt;210&gt; 3

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 3

Tyr Pro His Phe Met Pro Thr Asn Leu

1

5

&lt;210&gt; 4

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 4

Tyr Pro His Phe Met Pro Thr Asn Leu Arg Pro Gln Ala Ser Gly Val

1

5

10

15

Tyr Met Thr Tyr Gln Arg Thr Arg Ala Leu Val Ser Tyr Ile Pro Ser

20

25

30

Ala Glu Lys Ile

35

&lt;210&gt; 5

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 5

Arg Pro Gln Ala Ser Gly Val Tyr Met

1

5

- 3 -

<210> 6  
<211> 9  
<212> PRT  
<213> synthetic construct

<400> 6  
Thr Tyr Gln Arg Thr Arg Ala Leu Val  
1 5

<210> 7  
<211> 9  
<212> PRT  
<213> synthetic construct

<400> 7  
Ser Tyr Ile Pro Ser Ala Glu Lys Ile  
1 5

<210> 8  
<211> 5  
<212> PRT  
<213> synthetic construct

<400> 8  
Cys Asx Gln Cys Ala  
1 5

- 4 -

&lt;210&gt; 9

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 9

Tyr Pro His Phe Met Pro Thr Asn Leu Thr Ser Ser Gly Pro Ser Asn  
1 5 10 15

Thr Pro Pro Glu Ile Phe Ala Pro Gly Asn Tyr Pro Ala Leu Ser Tyr  
20 25 30

Ile Pro Ser Ala Glu Lys Ile Glu Glu Gly Ala Ile Val Gly Glu Ile  
35 40 45

Arg Pro Gln Ala Ser Gly Val Tyr Met  
50 55